Table 2.

Univariate and multivariate analyses of OS in patients with ccRCC in the TCGA database.

Variable	Mean survival (Mo)	95% CI	Univariate analysis		Multivariate analysis
			HR (95% CI)	P value	HR (95% CI)	P value
Total	44.9	42.0–47.9
Age (years)
≤60	46.9	42.6–51.2	Ref
>60	43	39–47.1	1.61 (1.17–2.21)	0.004	1.25 (0.9–1.75)	0.188
Sex
Female	45	39.6–50.3	Ref
Male	44.9	41.4–48.5	0.96 (0.69–1.34)	0.811
Race
Asian	30.6	17.1–44.2	Ref
Black	26.2	19.2–33.1	2.01 (0.26–15.7)	0.507
White	47.3	44.1–50.4	1.89 (0.26–13.52)	0.527
T classification
T1+T2	47.6	44–51.3	Ref
T3+T4	41	36–46.1	2.88 (2.09–3.97)	<0.001	0.64 (0.34–1.2)	0.164
N classification
N0	45.2	40.8–49.5	Ref
N1	27.2	11.7–42.6	2.81 (1.36–5.83)	0.005
M classification
M0	47.1	43.9–50.3	Ref
M1	35.2	27.4–43.1	4.57 (3.3–6.32)	<0.001	1.31 (0.84–2.05)	0.236
TNM stage
I+II	48	44.4–51.7	Ref
III+IV	40.2	35.3–45	3.61 (2.59–5.03)	<0.001	2.54 (1.19–5.41)	0.016
Histologic grade
G1+G2	46.6	42.4–50.9	Ref
G3+G4	43.5	39.4–47.6	2.63 (1.83–3.76)	<0.001	1.57 (1.06–2.32)	0.024
Tumor status
Tumor-free	46.5	43.1–50	Ref
With tumor	40.9	35.3–46.4	5.41 (3.89–7.53)	<0.001	4.75 (2.32–9.75)	<0.001
Laterality
Left	43.5	39.4–47.7	Ref
Right	46.2	42–50.3	0.66 (0.48–0.91)	0.010	0.73 (0.53–1.01)	0.057
Relapse
No	45.3	41.8–48.8	Ref
Yes	44.2	38.7–49.8	4.17 (3.0–5.8)	<0.001	0.64 (0.31–1.32)	0.225
Neoadjuvant treatment history
No	45.1	42.1–48.1	Ref
Yes	39.7	24–55.3	2.19 (1.15–4.16)	0.017	1.22 (0.62–2.39)	0.561
PKMYT1 expression
Low	47.7	43.7–51.7	Ref
High	42.1	37.8–46.4	1.82 (1.32–2.52)	<0.001	1.79 (1.29–2.49)	0.001

OS – overall survival; ccRCC – clear cell renal cell carcinoma; TCGA – The Cancer Genome Atlas; HR – hazard ratio; 95% CI – 95% confidence interval.